Clinical Trials Logo

Filter by:
NCT ID: NCT03927937 Recruiting - Tooth Loss Clinical Trials

Tooth Autotransplantation and Bone Dimension Changes

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

Tooth autotransplantation is a treatment option to replace tooth with imposible prognosis. In several cases the receipt site has a reduced bone dimension. This situation may be imposible the treatment with dental implants without bone reconstruction. Autotransplantation seem to improve the anatomic characteristic of the receipt site without any reconstruction approach. The aim of this study is to evaluate the bone dimension changes followed autotransplantation treatment.

NCT ID: NCT03926988 Recruiting - Clinical trials for Acute Ischemic Stroke

The Vesalio NeVa Stent Retriever Registry Study for Treatment of Large Vessel Occlusion Strokes

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

A prospective, open label, 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.

NCT ID: NCT03922204 Recruiting - Advanced Cancer Clinical Trials

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Start date: May 8, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary efficacy of MCLA-145 in advanced or metastatic malignancies

NCT ID: NCT03922100 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Start date: April 3, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).

NCT ID: NCT03921502 Recruiting - Choledocholithiasis Clinical Trials

Clinical Trial Comparing ERCP vs ERCP and Transmural Gall Bladder Drainage

PECAS
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

Cholelithiasis occurs in 10-20% of the general population. Up to 18% of these subjects will present symptoms. In patients with symptomatic choledocholithiasis who are not candidates for surgery with indication for ERCP, transmural drainage of the gallbladder reduces the risk of recurrence. The investigators propose a multicentric double-blind randomized trial. Our primary objective is to assess whether ERCP associated with transmural gallbladder drainage is able to reduce biliary disease income compared with ERCP in patients not candidates for surgery with symptomatic choledocholithiasis and cholelithiasis during one year of follow-up. Also the investigators will analyze the proportion of technical success and complications. The study population includes all patients older than 75 years with symptomatic choledocholithiasis. An estimated 75 subjects per group (ERCP alone and ERCP and transmural drainage) are needed.

NCT ID: NCT03918798 Recruiting - Hernia, Inguinal Clinical Trials

The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population

Start date: February 14, 2019
Phase: Phase 2
Study type: Interventional

Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial to evaluate the efficacy and safety of local anesthetic Chloroprocaine at two different concentrations ( at 1% and 2%) in a pediatric population subjected to peripheral nerve block due to Inguinal hernia repair or Flat foot surgery. The present Protocol is part of an extensive Pediatric Investigational Plan (PIP) in the contest of the marketing authorization application of chloroprocaine use for perineural block. The PDCO has adopted a positive opinion.

NCT ID: NCT03918564 Recruiting - Obesity Clinical Trials

ReShape Vest™ for the Treatment of Obesity (Europe)

Start date: March 25, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

To assess the safety and effectiveness of the LGV in treating obese subjects with a BMI of 35 kg/m2 to 55 kg/m2 who have failed one or more conservative weight-reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s).

NCT ID: NCT03916471 Recruiting - Clinical trials for Stress Urinary Incontinence

Comparison of Efficacy and Side Effects Between the Obtryx and Solyx Band With 5-year Follow-up.

Start date: December 21, 2018
Phase: N/A
Study type: Interventional

Boston2018 post-market clinical study is a prospective, randomized, non-inferiority study to assess the efficacy and adverse events of the Solyx™ Single Incision Sling (SIS) System compared to the gold-standard Obtryx™ II Sling System, in patients with stress urinary incontinence (SUI) and long-term follow-up (5 years).

NCT ID: NCT03915522 Recruiting - Knee Osteoarthritis Clinical Trials

Adductor Canal Block in an Enhanced Recovery Program After Total Knee Arthroplasty

Start date: May 14, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effectivity of adductor canal block performed the day after total knee arthroplasty surgery in reducing pain and improving walking ambulation ability and muscle strength.

NCT ID: NCT03914209 Recruiting - Haemophilia Clinical Trials

Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia

Start date: June 2, 2020
Phase:
Study type: Observational

Background. Hemophiliac arthropathy is the main long-term physical damage in patients with hemophilia, causing disability and functional limitations. Objective. Assessment of the efficacy of a prophylactic treatment with EHL products for improving the musculoskeletal health of adult patients with hemophilia. Study Design. Multicenter observational clinical study. Method. 40 patients with hemophilia A will be included in this study. Patients will be recruited from 5 centers located in various regions of Spain (Community of Madrid, Galicia, Community of Valenciana, Málaga and Vizcaya). The dependent variables will be: bleeding frequency (self-report of bleeding), changes in the dosage of factor VIII with EHL products (rFVIIIFc), pain (measured with the visual analog scale and a pressure Algometer), degree of kinesiophobia (Tampa Scale of Kinesiophobia), degree of adherence to treatment (Veritas-Pro scale), joint health (using the Hemophilia Joint Health Score), muscle strength (using a dynamometer) and functionality (using the 6-Minute Walking Test). Three evaluations will be carried out: baseline, at 6 months, and at the end of the study period, at 12 months. The evolution of quantitative variables shall be analyzed by parametric tests (t-student test) or non-parametric tests (Wilcoxon test). Pearson's correlation coefficient shall be used to obtain the correlation between the dependent and independent variables. By means of a linear regression analysis we will record the percentage influence of the clinical variables relative to the dependent variables measured in this study Expected results. The aim is to establish the effectiveness of the prophylactic treatment in the improvement of the state health, joint pain, muscle strength and functionality in patients with hemophilia.